Measles susceptibility in maternal-infant dyads-Bamako, Mali.
Maternal antibodies
Measles
Measles immunization
Measles plaque reduction neutralization
Mother-infant
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
23 02 2022
23 02 2022
Historique:
received:
23
07
2021
revised:
26
12
2021
accepted:
10
01
2022
pubmed:
2
2
2022
medline:
11
3
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Measles is endemic in Africa; measles mortality is highest among infants. Infant measles antibody titer at birth is related to maternal immune status. Older mothers are likelier to have had measles infection, which provides higher antibody titers than vaccine-induced immunity. We investigated the relationship between maternal age and measles susceptibility in mother-infant pairs in Mali through six months of infancy. We measured serum measles antibodies in 340 mother-infant pairs by plaque reduction neutralization test (PRNT) and calculated the proportion of mothers with protective titers (>120 mIU/mL) at delivery and the proportion of infants with protective titers at birth, and at three and six months of age. We explored associations between maternal age and measles antibodies in mothers and infants at the timepoints noted. Ten percent of Malian newborns were susceptible to measles; by six months nearly all were. Maternal and infant antibody titers were highly correlated. At delivery, 11% of mothers and 10% of newborns were susceptible to measles. By three and six months, infant susceptibility increased to 72% and 98%, respectively. Infants born to younger mothers were most susceptible at birth and three months. Time to susceptibility was 6.6 weeks in infants born to mothers with measles titer >120-<430 mIU/mL versus 15.4 weeks when mothers had titers ≥430 mIU/mL. Maternal and newborn seroprotective status were positively correlated. Improved strategies are needed to protect susceptible infants from measles infection and death. Increasing measles immunization coverage in vaccine eligible populations, including nonimmune reproductive-aged women and older children should be considered.
Identifiants
pubmed: 35101263
pii: S0264-410X(22)00027-5
doi: 10.1016/j.vaccine.2022.01.012
pmc: PMC8861573
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1316-1322Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
J Prev Med Hyg. 2014 Mar;55(1):33-4
pubmed: 25916031
PLoS One. 2013;8(2):e55682
pubmed: 23437059
J Infect Dis. 1990 Nov;162(5):1036-42
pubmed: 2230231
Epidemiol Infect. 1996 Dec;117(3):519-24
pubmed: 8972678
MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705
pubmed: 33180759
J Infect Dis. 2011 Jul;204 Suppl 1:S133-48
pubmed: 21666154
Bull Soc Pathol Exot. 1991;84(5 Pt 5):885-97
pubmed: 1819436
Vaccine. 1997 Apr-May;15(6-7):620-3
pubmed: 9178461
BMJ. 2010 May 18;340:c1626
pubmed: 20483946
Vaccine. 2003 Jun 20;21(21-22):2948-53
pubmed: 12798638
Vaccine. 2016 Jul 29;34(35):4119-4122
pubmed: 27340096
Vaccine. 2001 Oct 12;20(1-2):226-34
pubmed: 11567768
Clin Infect Dis. 2000 Jul;31(1):110-9
pubmed: 10913406
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992389
Clin Infect Dis. 2001 Nov 15;33(10):1720-7
pubmed: 11595986
Pediatrics. 1995 Sep;96(3 Pt 1):447-50
pubmed: 7651776
Vaccine. 2008 Nov 25;26(50):6392-7
pubmed: 18834911
Am J Trop Med Hyg. 2005 Jul;73(1):26-31
pubmed: 16014826
Vaccine. 2007 Dec 21;26(1):59-66
pubmed: 18063236
BMC Infect Dis. 2018 Aug 14;18(1):400
pubmed: 30107824
Trans R Soc Trop Med Hyg. 1972;66(1):176-82
pubmed: 5048071
Lancet Infect Dis. 2016 Sep;16(9):1026-1035
pubmed: 27261067
J Infect Dis. 2003 May 15;187 Suppl 1:S69-73
pubmed: 12721894
Front Immunol. 2020 Mar 31;11:555
pubmed: 32296443
J Infect Dis. 2019 Oct 22;220(11):1771-1779
pubmed: 30923799
Pediatr Infect Dis J. 1992 Jul;11(7):525-9
pubmed: 1528642